Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
复制标题
DOI:
10.1016/j.tibs.2018.09.004
复制
发表时间:
2018-12
影响因子:
13.8
通讯作者:
Wei W
中科院分区:
文献类型:
--
作者:
Zhang J;Dang F;Ren J;Wei W
PD-L1, frequently expressed in human cancers, engages with PD-1 on immune cells and contributes to cancer immune evasion. As such, antibodies blocking the PD-1/PD-L1 interaction reactivate cytotoxic T cells to eradicate cancer cells. However, a majority of cancer patients fail to respond to PD-1/PD-L1 blockade with unclear underlying mechanism(s). Recent studies revealed that PD-L1 expression levels on tumor cells might affect the clinical response to anti-PD-1/PD-L1 therapies. Hence, understanding molecular mechanisms for controlling PD-L1 expression will be important to improve the clinical response rate and efficacy of PD-1/PD-L1 blockade. In this review, we primarily focus on summarizing PD-L1 regulation and its potential roles in regulating anti-tumor immune response, with purpose to optimize anti-PD-1/PD-L1 therapies, benefiting a wider cancer patient population.
登录
查看更多内容
DOI:
10.1111/j.1365-2613.2010.00734.x
发表时间:
2010-12-01
影响因子:
3
作者:
Barry, Sean P.;Townsend, Paul A.;Stephanou, Anastasis
通讯作者:
Stephanou, Anastasis
影响因子:
28.5
作者:
Bi XW;Wang H;Zhang WW;Wang JH;Liu WJ;Xia ZJ;Huang HQ;Jiang WQ;Zhang YJ;Wang L
通讯作者:
Wang L
DOI:
10.1126/science.aac9935
发表时间:
2016-04-08
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Casey SC;Tong L;Li Y;Do R;Walz S;Fitzgerald KN;Gouw AM;Baylot V;Gütgemann I;Eilers M;Felsher DW
通讯作者:
Felsher DW
影响因子:
11.2
作者:
Barsoum, Ivraym B.;Smallwood, Chelsea A.;Graham, Charles H.
通讯作者:
Graham, Charles H.
影响因子:
5
作者:
Andersen, J.;VanScoy, S.;Reich, N. C.
通讯作者:
Reich, N. C.